Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid

Lung Cancer. 2017 Dec:114:111-112. doi: 10.1016/j.lungcan.2017.10.010. Epub 2017 Oct 28.

Authors

Sandrine Théoleyre¹, Ingrid Masson¹, Guillaume Herbreteau¹, Audrey Vallée¹, Hélène Sénellart¹, Marc G Denis²

Affiliations

¹ Nantes University Hospital & Integrated Center for Oncology, Nantes, France.
² Nantes University Hospital & Integrated Center for Oncology, Nantes, France. Electronic address: marc.denis@chu-nantes.fr.

PMID: 29096978
DOI: 10.1016/j.lungcan.2017.10.010

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acrylamides
Aniline Compounds
Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Cerebrospinal Fluid
Drug Resistance, Neoplasm / drug effects
Drug Resistance, Neoplasm / genetics*
ErbB Receptors / analysis
ErbB Receptors / genetics*
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Meningeal Carcinomatosis / drug therapy
Meningeal Carcinomatosis / secondary
Middle Aged
Mutation
Piperazines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use

Substances

Acrylamides
Aniline Compounds
Antineoplastic Agents
Piperazines
Protein Kinase Inhibitors
osimertinib
EGFR protein, human
ErbB Receptors